R-Tech Ueno, Ltd. is engaged in the research, development, manufacture, and sale of pharmaceutical products for the treatment of ophthalmology and dermatology worldwide. The company offers Rescula eye drops to treat glaucoma and ocular hypertension. Its product pipeline comprises Rescula/UF-021, which is in Phase IIb clinical trials to treat retinitis pigmentosa; RU-101 which is in Phase IIa clinical trials for the treatment of dry eye; and RK-023 that is in Phase IIa clinical trials to treat alopecia, as well as in Phase I clinical trials to treat hypotrichosis of the eyelashes. The company is also developing RTU-007 for treating diabetic cataract and retinopathy, and age-related macula degeneration; RTU-1096 for the treatment of atopic dermatitis, contact dermatitis, psoriasis, and diabetic neuropathy. In addition, it offers R and D assistance services, including development of synthetic methods; contract manufacturing of pharmaceuticals; characterization studies; formulation studies; and quality tests and stability tests for drug substances and drug products. Further, the company is engaged in contract manufacturing of injections, eye drops, liquid drugs, liquid-filled hard capsules, solid formulations, and ointments. R-Tech Ueno, Ltd. was founded in 1989 and is headquartered in Tokyo, Japan.
r-tech ueno ltd
(4573:Tokyo Stock Exchange)
NBF Hibiya Builing
Phone: 81 3 3596 8011
Fax: 81 3 3596 8023www.rtechueno.com
|No competitor information is available for 4573.|
|View Industry Companies|
Sponsored Financial Commentaries
To contact R-TECH UENO LTD, please visit www.rtechueno.com. Company data is provided by Capital IQ. Please use this form to report any data issues.